[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568375":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":24,"centralContacts":28,"locations":33,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":10,"enrollmentInfo":63,"targetDuration":10,"studyType":66,"phases":10,"briefSummary":67,"conditions":68,"keywords":10,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","OTHER",[8,12,15,18,21],{"label":9,"type":10,"description":11,"interventionNames":10},"Group A",null,"Patients newly diagnosed with advanced EE starting active surveillance",{"label":13,"type":10,"description":14,"interventionNames":10},"Group B","Patients with new diagnosis of advanced, evolving EE, worthy of medical treatment",{"label":16,"type":10,"description":17,"interventionNames":10},"Group C","Patients with a previous diagnosis of advanced EE, already under active surveillance",{"label":19,"type":10,"description":20,"interventionNames":10},"Group D","Patients with a previous diagnosis of advanced EE with ongoing medical treatment",{"label":22,"type":10,"description":23,"interventionNames":10},"Group E","Patients with localized EHE",[25],{"name":26,"affiliation":5,"role":27},"Silvia Stacchiotti","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":10,"email":32},"CONTACT","0223902803","Silvia.Stacchiotti@istitutotumori.mi.it",[34],{"facility":35,"status":36,"city":37,"state":10,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Fondazione IRCCS IstitutoNazionale dei Tumori","RECRUITING","Milan","20133","Italy","IT",{"type":42,"coordinates":43},"Point",[44,45],9.18951,45.46427,{"lat":45,"lon":44},[48,49],{"name":26,"role":30,"phone":10,"phoneExt":10,"email":32},{"name":50,"role":30,"phone":10,"phoneExt":10,"email":51},"Anna Maria Frezza","annamaria.frezza@istitutotumori.mi.it",{"type":53,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100568375","epithelioid-haemangioendothelioma-observational-study-100568375",false,"NCT06680401","Epithelioid Haemangioendothelioma Observational Study","The Evaluation of Cytokines and Hormones as Biomarkers for Epithelioid Haemangioendothelioma and Generation of Patient-derived Preclinical Models to Assess the Activity of Anticancer Agents and Validate Novel Therapeutic Targets","Inclusion Criteria:\n\n* Histological diagnosis of EHE according to 2020 WHO classification, performed on biopsy or surgical specimen\n* Signed informed consent\n* Adequate patient compliance to treatment or follow up\n* No age limit\n\nExclusion Criteria:\n\n* Impossibility to ensure adequate compliance","ALL","18 Years",{"count":64,"type":65},50,"ESTIMATED","OBSERVATIONAL","The EHE observational study was developed to obtain a high number of datas such as clinical presentation, natural history, and treatment outcomes, cto identificate cytokines and hormones as biomarkers and generate patient-derived preclinical models as a tool to assess the activity of anticancer agents and validate novel therapeutic targets",[69,70,71],"Clinical Presentation","Natural History","Treatment Outcomes","2026-03-27",{"date":74,"type":75},"2026-04-01","ACTUAL",{"date":77,"type":75},"2021-02-25",{"date":79,"type":65},"2028-12",{"name":5,"class":6},1]